Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
Lori Muffly, Vandana Sundaram, Connie Chen, Ilana R. Yurkiewicz, Eric Kuo, Sarah Burnash, Jay Y. Spiegel, Sally Arai, Matthew J. Frank, Laura Johnston, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, Surbhi Sidana, Parveen Shiraz, Judith A. Shizuru, Wen‐Kai Weng, Michaela Liedtke, Hyma T. Vempaty, David B. Miklos
Abstract
Monitoring of measurable residual disease (MRD) is essential to the management of acute lymphoblastic leukemia (ALL) and is typically performed through repeated bone marrow (BM) assessments. Using a next-generation sequencing (NGS) MRD platform, we performed a prospective observational study evaluating the correlation between peripheral blood (PB) and BM MRD in adults with ALL receiving cellular therapies (hematopoietic cell transplantation [HCT] and chimeric antigen receptor T-cell [CAR-T] therapies). Among the study cohort (N = 69 patients; 126 paired PB/BM samples), we found strong correlation between PB and BM MRD (r = 0.87; P < .001), with a sensitivity and specificity of MRD detection in the PB of 87% and 90%, respectively, relative to MRD in the BM. MRD became detectable in the PB in 100% of patients who subsequently relapsed following HCT, with median time from MRD+ to clinical relapse of 90 days, and in 85% of patients who relapsed following CAR T, with median time from MRD+ to clinical relapse of 60 days. In adult patients with ALL undergoing cellular therapies, we demonstrate strong concordance between NGS-based MRD detected in the PB and BM. Monitoring of ALL MRD in the PB appears to be an adequate alternative to frequent invasive BM evaluations in this clinical setting.